LQ036

BIOLOGICAL2 trials

Sponsors

Syneos Health, Shanghai Novamab Biopharmaceuticals Co., Ltd.

Conditions

Asthma

Phase 1

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

TerminatedNCT04993443

Syneos HealthAsthma

Start: 2021-09-06End: 2023-03-09Updated: 2023-04-13

Phase 2

Dose-Ranging Study of LQ036 Single-Domain Antibody Nebulization Solution in Poorly Controlled Asthma

RecruitingNCT07589439

Shanghai Novamab Biopharmaceuticals Co., Ltd.Asthma

Start: 2025-09-30End: 2027-12-01Target: 216Updated: 2026-06-25